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ABSTRACT CaMBP, a peptide corresponding to the 3614–3643 calmodulin (CaM) binding region of the ryanodine receptor
(RyR1), is known to activate RyR1 Ca21 channel. To analyze the mechanism of channel regulation by the CaMBP-RyR1 inter-
action, we investigated a), CaMBP binding to RyR1, b), induced local conformational changes in the CaMBP binding region of
RyR1 using the ﬂuorescent conformational probe badan attached to CaMBP (CaMBP-badan), and c), effects of ‘‘a’’ and ‘‘b’’ on SR
Ca21 release. We also monitored the interaction of CaMBP-badan with CaM and a peptide corresponding to the Met3534–Ala4271
region of RyR1 (R3534–4271) as a control. At lower peptide concentrations (#15 mM), CaMBP binding to RyR1 increased the
intensity of badan ﬂuorescence emission at a shorter wavelength (the state resembling CaMBP-badan/Ca-CaM) and induced
Ca21 release. Further increase inCaMBPconcentration (up to;50mM)producedmore bindingofCaMBPaccompaniedby further
increase in the badan ﬂuorescence emission but at a longer wavelength (the state resembling CaMBP-badan/apo-CaM) and
inhibited Ca21 release. Binding of CaMBP-badan to R3534–4271 increased the intensity of badan ﬂuorescence, showing the
similar concentration-dependent red-shift of the emission maximum. It is proposed that CaMBP interacts with two classes of
binding sites located in the Met3534–Ala4271 region of RyR1, which activate and inhibit the Ca21 channel, respectively.
INTRODUCTION
Calmodulin (CaM) regulates Ca21 channels of the skeletal
and cardiac isoforms of the ryanodine receptor (RyR1 and
RyR2, respectively) in a Ca21-dependent manner (also in a
manner characteristic of each RyR isoform (1–3)) presum-
ably by binding via its C-terminal lobe (4). In RyR1, CaM
increases RyR channel activity at lower (nanomolar to sub-
micromolar) Ca21 concentrations whereas it inhibits channel
activity at higher (micromolar to submillimolar) Ca21 con-
centrations (5–9). In the case of RyR2, however, CaM
inhibits channel activity at all Ca21 concentrations (6,10,11).
In both RyR1 and RyR2 isoforms, one CaM binds to one
subunit of RyR (6,12). In the case of RyR1, CaM binding
seems to take place within the region encompassing resi-
dues 3614–3643 (12–17). The region encompassing residues
3583–3603 of RyR2 is highly homologous to the residues
3614–3643 of RyR1; furthermore, mutation of several critical
residues in this region abolished CaM binding to RyR2 as it
does to RyR1 (18). Thus, it appears that RyR1 and RyR2 have
at least one common CaM binding domain (CaMBD) in the
corresponding 3614–3643 and 3583–3603 regions, respec-
tively, and this CaM binding region seems to play a central
role in the mechanism of Ca21/CaM-dependent channel
regulation.
The mode of CaM regulation at low Ca21 concentrations
is quite distinguishable between RyR1 and RyR2, as de-
scribed above. According to a recent report by Meissner and
his colleagues (19), the two regions outside of the 3614–
3643 CaM binding region—the region located at the
N-terminal side of the CaM binding region and the one at the
C-terminal side—seem to be involved in the isoform-speciﬁc
Ca21/CaM-dependent regulation. It has also been suggested
that there are secondary CaM binding sites in the 1975–1999
residue region of RyR1 (20) and in the C-terminal tail region
of the a1 subunit of the dihydropyridine receptor (21). These
pieces of information suggest that multiple regions of the
RyR polypeptide chain may be involved in the mechanism of
Ca21/CaM-mediated regulation of RyR1 Ca21 channel,
although the stoichiometry of binding is one CaM per
subunit of the RyR. Of particular interest in this context is a
recent report by Zhu et al. (22) that CaMBP, a synthetic
peptide corresponding to the 3614–3643 CaM binding
region of RyR1, activates RyR1 channels. This suggests
that not only the CaM binding region but also yet uniden-
tiﬁed regulatory domains of RyR1, with which the CaMBP
peptide (perhaps the in vivo CaM binding domain as well)
interacts, are involved in Ca21 channel regulation. Accord-
ing to a recent work of Hamilton and her colleagues (23),
there is a segment (residues 4064–4210) in the RyR1
polypeptide chain that resembles the sequence structure of
CaM (CaM-like domain within the RyR1), and the expressed
peptide corresponding to this segment has several CaM-like
properties; importantly, the expressed peptide binds with
CaMBP. Thus, the pieces of new information accumulated to
date suggest a hypothesis that not only the 3614–3643 region
of CaMBD but also the 4064–4210 CaMBP binding/CaM-
like domain (CaMLD) are involved in the Ca21- and CaM-
mediated channel regulation. Since CaMBP seems to retain
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several important properties of its corresponding in vivo
domain (i.e., CaMBD) and it binds to the expressed peptide
corresponding to the CaMLD, it is not unreasonable to
assume that the interaction between the CaMBD and the
CaMLD are involved in channel regulation (cf. 23).
In our recent study of the interaction between CaMBP
and CaM (24), we used a highly environment-sensitive ﬂuo-
rescent probe, 6-bromoacetyl-2-dimethylaminonaphthalene
(badan), and demonstrated that the badan probe attached
either to CaM (CaM-badan) or CaMBP (CaMBP-badan) can
serve as an excellent reporter of the changes in the local en-
vironment of the CaM/CaMBP interaction interface and of
protein conformational changes in the CaM molecule in-
duced by its binding with CaMBP. Thus, the ﬂuorescence
intensity of the CaMBP-badan increased considerably upon
binding with CaM. Furthermore, the magnitude of the ﬂuo-
rescence increase of CaMBP-badan induced by the interac-
tion with CaM increased further with Ca21 in a physiological
range (0.1–2 mM), although CaMBP-badan alone (without
interaction with CaM) showed no such change. Importantly,
the Ca21-dependent ﬂuorescence changes of the CaM-CaMBP
complex were identical regardless of whether the badan probe
was attached to CaM or CaMBP. These ﬁndings indicate that
CaMBP-badan can serve as an excellent spectroscopic probe to
monitor local conformational changes in the CaMBP-interact-
ing domain of the RyR1.
The strategy we have taken in this study is to utilize the
aforementioned advantage of CaMBP-badan to monitor the
peptide-induced conformational changes in its target domain
of the RyR1 and resultant Ca21 release from the SR. In this
study, we investigated concentration-dependent effects of
CaMBP on Ca21 release from the SR vesicles; in parallel to
the Ca21 release experiments, we monitored CaMBP bind-
ing to the SR and the CaMBP-induced local conformational
changes within the CaMBP-RyR interaction interface. To
facilitate the interpretation of the data of these experiments,
we also monitored the interaction between CaMBP-badan
and CaM and the interaction between CaMBP-badan and
the expressed peptide R3534–4271. We report here that the
CaMBP-induced protein conformational changes in the
RyR and those in the R3534–4271 share common properties
in the basic aspects, suggesting that the 3534–4271 region
of RyR1 containing both the CaMBD and the CaMLD is
involved in the mechanism of CaMBP-mediated channel
regulation. Coordinated analysis of the three parameters
(CaMBP binding, local conformational changes, and effects
on SR Ca21 release) led us to a new hypothesis that CaMBP
(presumably the corresponding in vivo domain, CaMBD,
as well) interacts with two distinguishable sites located in
the 3534–4271 region of RyR1, producing activation and
inhibition of the RyR1 Ca21 channel. The spectroscopic
properties of the RyR1-bound CaMBP-badan at the activat-
ing concentration and at the inhibitory concentration were
similar to those of Ca-CaM-bound CaMBP-badan and apo-
CaM-bound CaMBP-badan, respectively, suggesting that the
main CaMBP binding sites are located in the CaMLD de-
scribed by Xiong et al. (23).
EXPERIMENTAL PROCEDURES
Preparation of SR
Triad-enriched microsomal fraction (SR) was prepared from the rabbit back
paraspinous and hind leg skeletal muscle by the method of differential centri-
fugation as described previously (25). The microsomes from the ﬁnal centri-
fugation were homogenized in a sample solution containing 0.3 M sucrose,
0.15 M KCl, proteolytic enzyme inhibitors (0.1 mM phenylmethanesulfonyl
ﬂuoride, 1mg/ml leupeptin, 2.0mg/ml soybean trypsin inhibitor), 20 mM 2-(N-
morpholino)ethanesulfonic acid, pH 6.8 to a ﬁnal concentration of 20–30 mg/
ml, frozen immediately in liquid nitrogen and stored at 80C.
Peptide synthesis
3614KSKKAVWHKLLSKQRRRAVVACFRMTPLYN3643 . . . . . . . . . CaMBP
3614KSKKAVWHKLLSKQRRRAVV . . . . . . . . . F1
AVVACFRMTPLYN3643 . . . . . . . . . F4
CaMBP corresponding to RyR1 residues 3614–3643 was used as a peptide
model of the CaM binding region of RyR1. Two other peptides used, F1 and
F4, are derived from the peptide CaMBP. Peptides were synthesized on an
Applied Biosystems (Foster City, CA) model 431 A synthesizer employing
Fmoc (N-(9-ﬂuorenyl)methoxycarbonyl) as a-amino-protecting group and
cleaved and deprotected with 95% triﬂuoroacetic acid and puriﬁed by
reverse-phase high performance liquid chromatography. The peak fraction
was extensively dialyzed against distilled water, lyophilized, and stored at
80C.
Preparation of CaM
We used recombinant proteins overexpressed in Escherichia coli. The
cDNA of human liver CaM used in this study was a generous gift from Dr.
Richard Perham (Cambridge, UK) (26). The coding sequence with inclusion
of a short untranslated region was subcloned into pAED4—the T7 expres-
sion vector/Phagemid (a generous gift from Dr. Don S. Doering, Whitehead
Institute, Cambridge, MA) as previously described (27).
Fluorescence labeling of CaMBP
For site-speciﬁc labeling of CaMBP with the environment-sensitive ﬂuo-
rescent probe, badan (Molecular Probes, Eugene, OR) (28–30), 150 mg
CaMBP was reacted with 2 mM badan in a total volume of 1.0 ml solution
of 0.15 M KCl, 2 mM tris(2-carboxyethyl)phosphine, 20 mM 3-(N-
morpholino)propanesulfonic acid (MOPS) (pH 7.2). After incubation for 2 h
at 25C in the dark, the reaction was stopped with 30 mM b-mercaptoeth-
anol. The reaction mixture was loaded onto a Sephadex G-15 column. The
fraction containing CaMBP-badan was used for the spectroscopic experi-
ments. The concentration of the puriﬁed CaMBP-badan was determined
using the molar absorbance of badan of 20,100 cm1M1 at 386 nm.
Spectroscopic studies of CaMBP binding and
conformational changes in the CaMBP binding
region of RyR1
Stock solution of CaMBP-badan probe (90 mM) was made of 3 mM
CaMBP-badan as described above and 87 mM unlabeled CaMBP, and
various concentrations of CaMBP-badan probe indicated were made by
diluting this stock solution with the reaction buffer (for convenience, in the
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following part this solution is called CaMBP-badan solution). The
ﬂuorescence emission spectra of CaMBP-badan in the presence or absence
of SR or CaM were collected in a PerkinElmer (Wellesley, MA) spectro-
ﬂuorometer (model LS 50B) by exciting at 387 nm and by recording the
ﬂuorescence emission in the range 400–600 nm. Kinetic measurements of
the changes in badan ﬂuorescence produced by CaMBP binding and local
conformational changes were performed in a stopped-ﬂow spectroﬂuorom-
eter with excitation at 368 nm and emission at 455 nm using an interference
ﬁlter with 70 nm bandwidth. The free Ca21 concentration was calculated
from the amounts of 1,2-bis(o-aminophenoxy)ethane-N,N,N9,N9,-tetraacetic
acid (BAPTA) (1 mM), calcium (added CaCl2), and MgATP (1.0 mM) that
were present in the reaction solution by solving standard equilibrium
equations using the modiﬁed Catlig solution mixing computer program; and
various free Ca21 concentrations indicatedwere created by varying the amount
of calcium to be added on the basis of computer calculation.
CaMBP-induced Ca21 release
SR (0.2 mg/ml) in a solution of 20 mM MOPS, 0.15 M KCl, pH 7.2, 2 mM
ﬂuo-3 (Ca21 indicator) was loaded with Ca21 by 1 mMMgATP. Various con-
centrations of CaMBP were added to the Ca21 loaded SR to induce Ca21
release. The time course of CaMBP-induced Ca21 release was followed by
recording the changes in the ﬂuorescence intensity of ﬂuo-3 either in a
Perkin Elmer spectrophotometer (excitation at 488 nm, emission at 525 nm)
or in a stopped-ﬂow apparatus (Bio-Logic (Molecular Kinetics, Pullman,
WA) SFM-4) (excitation at 440 nm and emission at 510 nm using an
interference ﬁlter with a 40 nm bandwidth).
Construction and expression of R3534–4271
The peptide corresponding to residue 3534–4271 of RyR1 (R3534–4271)
was cloned in pET 100/D-TOPO vector using the Champion pET directional
TOPO Expression kit (Invitrogen, Carlsbad, CA). For this, the DNA
segment corresponding to R3534–4271 was ampliﬁed by polymerase chain
reaction with Pfu DNA Polymerase (Stratagene, La Jolla, CA) using the
plasmid containing a longer RyR1 fragment R2900–4272 as template (a
generous gift from Dr. James D. Fessenden, Boston Biomedical Research
Institute, Watertown, MA). The insertion and directionality were checked by
DNA sequencing. R3534–4271 construct was transformed in BL21 Star
(DE3) and expressed by inducing with isopropyl b-D-thiogalactoside at
37C for 3 h. The cells were harvested by centrifugation at 6500 3 g for 10
min, resuspended in buffer A (20 mM sodium phosphate, pH 7.0, 0.5 M
NaCl), and disrupted by sonication, followed by centrifugation at 16,5003 g
for 15min. As R3534–4271was expressed in inclusion bodies, the pellet was
resuspended in buffer B (buffer A supplemented with 8 M urea) to solubilize
the inclusion bodies and centrifuged at 16,500 3 g for 15 min. The
supernatant was loaded on the Talon metal afﬁnity column (BD Biosciences,
Franklin Lakes, NJ) preequilibrated with buffer B. The column was washed
with 2 3 1 ml of buffer B and 2 3 1 ml of buffer B supplemented with
10 mM imidazole. Elution was done with buffer B plus 150 mM imidazole.
The puriﬁed protein was refolded by dialysis against 20 mMMOPS, 0.15 M
KCl, pH 7.2 using 12,000–14,000 molecular weight cutoff membrane.
RESULTS
CaMBP is an on/off regulator of the
RyR1 Ca21 channel
In recent reports, Zhu et al. (22) have shown that sub-
micromolar concentrations of CaMBP enhanced ryanodine
binding to RyR1 in a Ca21-dependent manner, and Rodney
et al. (31) have shown that CaMBP increased the frequency
of Ca21 sparks and the activation is caused by a direct
interaction of CaMBP with RyR1, rather than by the peptide-
mediated dissociation of RyR1-bound CaM (22,31). Ac-
cording to Zhu et al. (22) a shorter peptide corresponding to
the N-terminal portion of CaMBP, F1 (according to their ter-
minology, see sequence diagram in ‘Experimental Proce-
dures’), retained the function of CaMBP to enhance ryanodine
binding, whereas its C-terminal portion, F4, was inhibitory.
As described in an earlier report by Rodney et al. (32) and in
our recent study (24), CaM binds to CaMBP producing con-
formational changes in both CaM and CaMBP (24,31,32),
and the F1 portion of CaMBP is sufﬁcient for the binding
with Ca-CaM, but both F1 and F4 portions are required for
the binding with apo-CaM, suggesting a Ca21-dependent
shift of CaM binding site toward the N-terminal side of
CaMBP (24 cf. 32). Thus, CaMBP seems to retain some struc-
tural and functional properties of the CaMBD of RyR1 and
may serve as a useful probe for the studies of the postulated
interaction between the CaMBD and the putative CaMBP
binding domain of RyR1 (see Introduction).
In the experiment shown in Fig. 1, we induced Ca21 re-
lease by adding various concentrations of CaMBP to the SR
vesicles and followed the release time course using ﬂuo-3 as a
Ca21 probe in a spectrophotometer (Fig. 1 A) or in a stopped-
ﬂow apparatus (Fig. 1 B). Our puriﬁed SR preparation con-
tained only a residual amount of the RyR1-bound CaM
(cf. 33), and the amount of the residual CaM did not change
after treatment of the SR with 50 mM CaMBP as determined
by Western blot analysis. Furthermore, if dissociation of the
bound CaM were the cause of the observed effect, the effect
of CaMBP would have been inhibition rather than activation,
because Ca21 release was triggered at submicromolar Ca21.
Therefore the CaMBP-induced Ca21 release seems to be
caused primarily by its interaction with the CaMBP binding
domain of the RyR1. As shown, both the rate and the am-
plitude of Ca21 release increased with an increase of the con-
centration of CaMBP up to;15 mM, but further increases of
CaMBP concentration resulted in a progressive decrease in
the rate and the amplitude of Ca21 release and reached nearly
zero at 50 mM. Fig. 2 shows the plot of the initial rate of
Ca21 release calculated from the ﬁtting of the data shown in
Fig. 1 A as a function of the concentration of CaMBP. This
steep concentration-dependent activation and inhibition
curve suggests that CaMBP binds to two classes of binding
sites on the RyR1 in a sequential manner: binding of CaMBP
to the ﬁrst binding site activates Ca21 release (with the extent
of activation, a, and the afﬁnity of binding, Ka), and further
binding of CaMBP to the second site inhibits Ca21 release
(with the extent of inhibition, b, and the afﬁnity of binding
Ki). The data shown in Fig. 2 were ﬁtted by an equation
based upon the above model: y ¼ faKma xm=ð11Kma xmÞg
f1 bKni xn=ð11Kni xnÞg; where y is the rate of Ca21 release
at x concentration of CaMBP, Ka and Ki are the association
constants, and m and n are the Hill coefﬁcients of peptide
binding to the activation site(s) and the inhibition site(s),
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respectively. The calculated values of Ka, Ki, m, and n were
7.85 3 104M1, 2.99 3 105M1, 2.86, and 7.26, respec-
tively. Interestingly, the estimated afﬁnity of the CaMBP
binding to the inhibitory site appears to be even higher than
that to the activating site, even though the inhibition of Ca21
release occurs after the activation of Ca21 release with an
increase of CaMBP concentration. This suggests that the ﬁrst
binding to the activating site prompts the second binding to
the inhibitory site and the former is prerequisite for the latter.
In contrast to the biphasic activation/inhibition pattern
of CaMBP-induced Ca21 release, the rate and the amplitude
of Ca21 release induced by F1 peptide increased with an
increase of the peptide concentration in monotonically up to
as high as 50 mM without showing any sign of inhibition
(Fig. 3). Fig. 3 also shows the time courses of Ca21 release
induced by 50 mM CaMBP and the release induced by a
mixture of 50 mM F1 and 50 mM F4 peptides for
comparison. As seen, both the rate and the magnitude of
F1-induced Ca21 release were considerably reduced by the
equimolar concentration of F4 peptide mixed with F1 pep-
tide, resulting in the release time course resembling the time
course with 50 mM CaMBP. These results are consistent
with the view deduced from the previous study of ryanodine
binding (22) that the channel activating function of CaMBP
is localized in its F1 region, whereas its inhibitory function is
localized in the F4 region.
CaMBP-badan serves as a useful spectroscopic
probe to monitor the interaction of CaMBP
with CaM
As shown in our recent study (24), the badan probe attached
either to CaM (CaM-badan) or CaMBP (CaMBP-badan) can
serve as an excellent reporter of the changes in the local en-
vironment of the CaM/CaMBP interaction interface and of
protein conformational changes in the CaM molecule in-
duced by its binding with CaMBP (Introduction). To facili-
tate the interpretation of the results of the ﬂuorescent probe
studies of the CaMBP-RyR1 interaction described below, we
carried out the same type of studies using the combination of
CaMBP-badan and CaM as a model. In these experiments,
we collected emission spectra with increased concentrations
of CaMBP-badan in the presence of 0.5 mM CaM or in its
absence at 0.1 mM Ca21 (apo-CaM model) or 200 mM Ca21
(Ca-CaM model), and the spectra of CaMBP-badan alone
were subtracted from the corresponding spectra of CaMBP-
FIGURE 1 Time courses of Ca21 release induced by various concentra-
tions of CaMBP. (A) Spectrophotometric traces of Ca21 release in a longer
timescale (60 s). (B) Stopped-ﬂow traces of Ca21 release in an earlier phase
of the release time course (15 s).
FIGURE 2 Initial rate of CaMBP-induced Ca21 release shows a biphasic
dependence on the concentration of CaMBP, showing bell-shaped curves. To
calculate the initial rate of Ca21 release, the time courses of Ca21 release were
ﬁtted to the equation y¼ y01 A1(1 exp(k13 t))1 A2(1 exp(k23 t)),
where A is the amount of Ca21 released, k is the rate constant, 1 and 2 are fast
and slow phases, respectively, and (dy/dt)t/0¼ A13 k11 A23 k2 represents
the initial rate.
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badan with CaM to see the net changes in the badan ﬂuo-
rescence due to the CaMBP-CaM interaction (Fig. 4 A). As
shown, the ﬂuorescence intensity increases with an increase
of the concentration of CaMBP and plateaued with 1.0 mM
CaMBP at 0.1mMCa21 and with 0.7mMCaMBP at 200mM
Ca21. Interestingly, thewavelength at the emissionmaximum
(lmax) remained constant at 500nmat 0.1mMCa
21 and475nm
at 200 mM Ca21, regardless of the concentration of CaMBP
added. This indicates that the CaMBP-CaM complex is in the
two clearly distinguishable conﬁgurations depending on the
Ca21 concentration.
An earlier study by Rodney et al. (32) and our recent study
(24) suggest that at low Ca21 (,0.1 mM) CaM binds to the
central area (encompassing both F1 and F4 regions) of the
CaMBP peptide, whereas at high Ca21 (.1 mM) CaM binds
to the F1 region of CaMBP. Based on this we propose that
the ﬂuorescence signal characterized by lower lmax repre-
sents a conformational state comparable to the state of CaM
that is bound to the F1 region of CaMBP, whereas the signal
characterized by higher lmax represents a state comparable
with the CaM bound to the F1/F4 region. In the experiment
of Fig. 4 B, we analyzed the emission spectra of the mixture
of 1.0 mM CaMBP-badan and 0.5 mM CaM at various Ca21
concentrations as indicated. The results indicate that there is
a clear transition of the lmax from 500 nm to 475 nm with an
increase of Ca21 concentration from 0.1 mM to 0.3 mM.
Importantly, this is the Ca21 concentration range where the
transition of the CaM function occurs from an activator to an
inhibitor of the RyR1 Ca21 channel. Thus, the distinct dif-
ference in the lmax value and in the shape of emission spectra
characteristic of the CaMBP-CaM complex at low and high
Ca21 concentrations provides an important clue to interpret the
data of the CaMBP-RyR1 (SR) interaction described below.
Spectroscopic monitoring of the interaction
between CaMBP and the RyR1
CaMBP-badan is a powerful tool to study the CaMBP-CaM
interaction, as shown in the experiments of Fig. 4 and in our
recent study (24). Therefore, we exploited CaMBP-badan as
a spectrometric probe for the study of the CaMBP-RyR1
interaction. We expected that CaMBP-badan would report
two components: a very rapid (time-irresolvable) increase in
the ﬂuorescence intensity owing to the binding of CaMBP to
FIGURE 3 Unlike the biphasic concentration depen-
dence of CaMBP-induced Ca21 release, F1 (activating seg-
ment of CaMBP)-inducedCa21 release shows amonophasic
concentration dependence of activation. Maximal activa-
tion of Ca21 release by 50 mM F1 is considerably reduced
if an equimolar concentration of F4 (inhibitory segment of
CaMBP) is added together with F1.
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its interacting domain of RyR1 and a time-resolvable portion
of the ﬂuorescence change owing to a local protein con-
formational change in the RyR induced by the binding of
CaMBP. To monitor the ﬂuorescence change corresponding
to the peptide binding,we collected families of emission spec-
tra at various concentrations of CaMBP-badan in the absence
and in the presence of SR as shown in Fig. 5. We then cal-
culated the ﬂuorescence intensity of the protein-bound
CaMBP-badan and the wavelength at the emission maxi-
mum by subtracting the emission spectrum of CaMBP-badan
alone from the emission spectrum of CaMBP-badan ob-
tained in the presence of SR, as we did in the experiment of
Fig. 4. It should be noted that the experiments shown in Fig.
5, A and B, were carried out under the same conditions as
those used for the Ca21 release experiments shown in Figs.
1–3 (viz. in the presence of 1 mM MgATP) to correlate the
peptide binding/conformation data with the pattern of chan-
nel activation and inhibition. Although we used unlabeled
CaMBP in the Ca21 release experiments, ﬂuorescence label-
ing of CaMBP seemed to have virtually no effect on the
activating function of CaMBP as tested with 30 mMCaMBP
solution containing no CaMBP-badan used for stopped-ﬂow
experiments of Ca21 release and 30 mM solution consisting
of 1 mM CaMBP-badan and 29 mM CaMBP, the identical
solution used for the spectroscopic measurements. Further-
more, 3 mM CaMBP-badan proper and 3 mM unlabeled
CaMBP showed the identical Ca21 release-inducing activity.
As shown in Fig. 5, A and B, there are several important
changes in the property of the emission spectrum upon
binding of CaMBP-badan to the SR in the presence of 1 mM
MgATP (the same conditions as Ca21 release experiments).
The intensity of badan ﬂuorescence corresponding to the
RyR1-bound CaMBP increases with an increase of CaMBP
concentration and levels off at ;20 mM, at which inhibition
FIGURE 4 Monitoring of interactions between CaMBP and CaM using big changes in the ﬂuorescence properties of CaMBP-badan upon its binding to CaM
as a measure. (A) Emission spectra with increasing concentrations of CaMBP-badan in the presence of 0.5 mM CaM at 0.1 mM and 200 mM Ca21.
The sensitivity of the ﬂuorescence recording at 200 mM Ca21 was reduced to ;1/3 of that at 0.1 mM. (B) Emission spectra with 1 mM CaMBP-badan and
0.5 mM CaM at various Ca21 concentrations. To calculate the CaM-bound CaMBP-badan ﬂuorescence proper, the emission spectrum of CaMBP-badan
alone was subtracted from the corresponding emission spectrum of CaMBP-badan in the presence of CaM.
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of Ca21 release begins. Interestingly, there is a small but ap-
preciable change in the lmax from 467 nm to 474 nm with an
increase of CaMBP-badan concentration from 0.54 mM to
20 mM. In light of the ﬁndings with the CaMBP-badan/CaM
model (Fig. 4), this suggests that low concentration of
CaMBP produced ﬁrst the Ca-CaM-like signal to activate
Ca21 channel and higher concentration of CaMBP produced
the apo-CaM-like signal to inhibit the channel.
To monitor rapid local protein conformational changes
within the RyR1 induced by CaMBP binding, we carried out
stopped-ﬂow measurements in parallel to the Ca21 release
experiments shown in Fig. 1 B. The data are shown in Fig. 6
(note that the initial jump in the ﬂuorescence intensity ascrib-
able to the CaMBP binding to the RyR1, i.e., time-unre-
solvable portion, is not shown in the ﬁgure). In the activating
concentration range of CaMBP (1–15 mM), CaMBP binding
produces a rapid and monophasic increase of badan ﬂuores-
cence in a concentration-dependent manner, reﬂecting a local
conformational change in the CaMBP binding domain of the
RyR1. In the higher concentration range of CaMBP, coin-
cident with the function of CaMBP becoming inhibitory, the
initial rapid increase in the badan ﬂuorescence is followed by
a rapid spontaneous decay. This is due to the aforementioned
red-shift of lmax caused by the conformational transition of
the CaMBP/CaMLD complex from the Ca-CaM type to the
apo-CaM type, because the stopped-ﬂow ﬂuorescence signal
was recorded through an interference ﬁlter with a slit
opening at 455 nm. Collectively, the results shown in Figs. 5
and 6 suggest that CaMBP-mediated channel activation is
accompanied by the formation of the CaMBP-RyR1 com-
plex characteristic of the CaMBP-CaM complex at higher
Ca21 (shorter lmax, Ca-CaM type), whereas CaMBP-mediated
channel inhibition is accompanied by the formation of the
complex characteristic of the CaMBP-CaM complex at lower
Ca21 (longer lmax, apo-CaM type).
The above results of the Ca21 release and CaMBP-badan
experiments together suggest that there are two classes of
CaMBP binding sites in the CaMBP binding domain of the
RyR1 and that CaMBP binding to these sites induced local
conformational changes: the binding to the ﬁrst site produces
the badan ﬂuorescence change characterized by a shorter
lmax (465 nm) and produces channel activation, and the bind-
ing to the second site produces the badan ﬂuorescence
change characterized by a longer lmax (474 nm) and pro-
duces channel inhibition.
In the experiment shown in Fig. 7 A, we used R3534–4271,
an expressed peptide corresponding to the Met3534–Ala4271
stretch (containing both CaMBD and CaMLD) of RyR1 to
carry out the same type of CaMBP-badan experiment as done
with SR and CaM. R3534–4271 was expressed in inclusion
bodies, which could be refolded in a soluble form by dialysis.
As shown, upon addition of increasing concentrations of
CaMBP-badan to R3534–4271 (0.5 mM) at 0.1 mMCa21, the
intensity of badan ﬂuorescence increased. This indicates that
the CaMBP binding domain is localized in the 3534–4271
region of RyR1. In support of the notion that the ﬂuorescence
increase represents CaMBP binding to the expressed peptide,
the addition of unlabeled CaMBP (5 mM) reversed the
ﬂuorescence increase that had been produced by CaMBP-
badan (Fig. 7 C). Interestingly, there is a small but appreciable
change in the lmax from 460 nm to 470 nmwith an increase of
CaMBP-badan concentration from 10 nM to 100 nM. This
suggests that as in the case of CaMBP-badan binding to the
RyR1 moiety of the SR (Fig. 5, A and B), CaMBP binds to the
FIGURE 5 (A) Changes in the emission spectra caused by the interaction of increasing concentrations of CaMBP-badan with SR in the presence of 1 mM
MgATP (under the same conditions as those used for the Ca21 release experiments). To calculate the RyR-bound CaMBP-badan ﬂuorescence proper, the
emission spectrum of CaMBP-badan alone was subtracted from the corresponding emission spectrum of CaMBP-badan in the presence of SR. B. The
ﬂuorescence intensity of the protein-bound CaMBP-badan (d) and changes in the wavelength of the emission maximum (s) zas a function of CaMBP-badan
concentration.
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two classes of binding sites in a sequential manner: the
binding to the ﬁrst site produces a conformational state
resembling that of the CaMBP bound with Ca-CaM, and the
binding to the second site produces the state similar to that of
the CaMBP bound with apo-CaM. The ﬁrst binding may
correspond to the channel activation state, and the second
binding to the channel inhibition state, although we can’t
monitor the activity of the channel in this case.
DISCUSSION
The region encompassing residues 3614–3643 of RyR1 has
been identiﬁed as a major CaM binding region, as supported
by various pieces of evidence as outlined in the Introduction.
A considerable amount of information accumulated to date
suggests that CaMBP, a synthetic peptide corresponding to
residues 3614–3643, retains several functional properties of
its in vivo counterpart (i.e., the CaMBD of RyR1). As shown
in an earlier study by Hamilton and her colleagues (32) and
our recent study (24), CaM binds to slightly different regions
of the CaMBP depending upon the Ca21 concentration; this
is interesting in view of the report that there is a signiﬁcant
Ca21-dependent shift in the location of the RyR1-bound
CaM as shown in a cryo-EM single particle analysis (34,35).
More precisely, both F1 and F4 portions of CaMBP are
required for CaM binding at lower Ca21 (submicromolar),
but the F1 portion is sufﬁcient for CaM binding at higher
Ca21 (larger than micromolar), suggesting that with an in-
crease of Ca21 from submicromolar tomicromolar (or higher)
ranges, the site of CaMbinding shifts from theC-terminal side
to the N-terminal side of CaMBP (cf. 32). According to a
recent report by Zhu et al. (22), CaMBP activated the RyR1
Ca21 channel, as evidenced by its strong enhancement of
ryanodine binding activity and its ability to induce SR Ca21
release in the whole cell system. A synthetic peptide corre-
sponding to the F1 region (F1 peptide) activated ryanodine
binding, whereas F4 peptide was inhibitory (22). A more
recent study by Rodney et al. (31) has shown that CaMBP
increases the frequency of Ca21 sparks in the saponin-
permeabilized skeletal muscle ﬁber in a highly cooperative
concentration-dependent manner. These ﬁndings suggest that
CaMBP binding to its target domain in the RyR1 activates
—or under certain conditions inhibits—the Ca21 channel and
the CaMBP binding domain may represent an important, but
not yet well explored, regulatory domain of RyR1. According
to a recent report by Xiong et al. (23), the 4064–4210 residue
segment of RyR1 shows a CaM-like sequence; the expressed
peptide corresponding to this region in fact showed CaM-like
properties in Ca21 binding and Ca21-induced conformational
changes, and importantly it did bind with CaMBP. Since
CaMBP corresponds to the CaM binding domain of RyR1,
Xiong et al. (23,36) suggested that the interaction between
the CaMLD, to which CaMBP binding takes place, with the
CaMBDmay serve as an intrinsic regulator of the RyR1 Ca21
channel.
FIGURE 6 Time-resolvable portion of the stopped-ﬂow traces of the
changes in the badan ﬂuorescence upon mixing various concentrations of
CaMBP-badan with SR, showing the time course of CaMBP-induced local
conformational changes. A large initial jump of the badan ﬂuorescence due
to CaMBP binding to the RyR1 (time-unresolvable portion) is not shown in
the ﬁgure. The experiments were carried out in the same reaction solution as
used for the Ca21 release experiments, except that ﬂuo-3 was excluded. Note
that in the activating concentration range of CaMBP (#10 mM), the peptide
induces monophasic ﬂuorescence increase, whereas in the inhibitory concen-
tration range ($15 mM) the time course of the badan ﬂuorescence change
becomes biphasic (an initial increase is followed by a rapid spontaneous
decay).
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As shown in our recent study (24), the highly conforma-
tionally sensitive ﬂuorescent probe badan that was attached
to the Cys residue of CaMBP could report conformational
changes within the CaM molecule induced by the interaction
with CaMBP. In this study, we utilized this unique capability
of CaMBP-badan to investigate the CaMBP-induced local
conformational changes and resultant Ca21 release from the
SR. In this study, we correlated the three key functional param-
eters using CaMBP and SR as an experimental model: i),
effects of CaMBP on channel regulation (Fig. 1B) (the kinetics
of CaMBP-induced Ca21 release and its inhibition); ii),
binding of CaMBP to the putative CaMLD of RyR1 (Fig. 5)
(titration of the protein-bound CaMBP-badan ﬂuorescence);
and iii), rapid conformational changes in the CaMBP binding
domain upon binding of CaMBP (Fig. 6) (rapid changes in the
badan ﬂuorescence uponCaMBP binding). Each of these three
parameters was investigated in the presence of MgATP at
near threshold concentrations of Ca21. Under these conditions,
CaMBP induced faster and larger Ca21 release from the SR
upon increasing the peptide concentration in a range of rela-
tively low concentrations (,15 mM). Upon increasing the
peptide concentration further, the Ca21 release activity was
suppressed and almost completely inhibited at ;50 mM. In
contrast to the biphasic activation/inhibition pattern, the bind-
ing of CaMBP proceeded in a monotonic fashion throughout
the activating and inhibitory concentration ranges (as deter-
mined by the ﬂuorescence titration assay) and it plateaus at the
concentration, where the maximal inhibition of Ca21 release
takes place. The correlation between the Ca21 release data and
the ﬂuorescence titration data, also a tight correlation between
FIGURE 7 (A) Changes in the emission spectra caused by the interaction of increasing concentrations of CaMBP-badan with R3534–4271. To calculate the
ﬂuorescence of the CaMBP-badan bound with R3534–4271, the emission spectrum of CaMBP-badan alone was subtracted from the corresponding emission
spectrum of CaMBP-badan (d) in the presence of R3534–4271. (B) The ﬂuorescence intensity of the protein-bound CaMBP-badan (d) and changes in the
wavelength of the emission maximum (s) as a function of CaMBP-badan concentration. The ﬂuorescence measurements were performed at 0.1 mM Ca21
adjusted with a BAPTA/calcium buffer. (C) Addition of unlabeled CaMBP (5 mM) to the CaMBP-badan/R3534–4271 produced a considerable decrease in the
ﬂuorescence intensity that had been achieved by the binding of CaMBP-badan.
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the transition in the conformational states of the CaMBP/RyR1
complex and that in the channel activation/inhibition pattern,
suggests the mechanistic model shown in Scheme 1.
Scheme 1 assumes that there are two classes of CaMBP
binding sites in the CaMBP binding domain of the RyR1: an
A site and an I site. Binding of CaMBP to the A site produces
a conformational state of the binding domain characterized
by a lower lmax. The spectroscopic property of this state
resembles that of the CaMBP-badan that is bound with Ca-
CaM (Fig. 4) and the CaMBP/Ca-CaM interaction is medi-
ated by CaM binding to the F1 region of CaMBP (22,24).
Therefore, we assume that the binding of CaMBP to the A
site of the binding domain takes place via the F1 region of
CaMBP. This state activates the Ca21 channel and induces a
rapid Ca21 release. At higher concentrations of CaMBP, addi-
tional CaMBP binds to the I site. This produces the con-
formational state characterized by a higher lmax, the state that
corresponds to the state of apo-CaM interacting with the F1/
F4 region of CaMBP. Therefore, the binding of CaMBP to the
I site seems to take place via the F1/F4 region of CaMBP, and
this produces the inhibition of Ca21 channel and Ca21 release.
As shown in these stopped-ﬂow traces of the badan ﬂuo-
rescence changes during the CaMBP-badan/SR interaction
under the Ca21 release conditions (in the presence ofMgATP),
there was a concentration-dependent transition from mono-
phasic to biphasic time course of conformational change.
This transition coincided with the concentration-dependent
transition from activation to inhibition of Ca21 release (Fig.
6, cf. Fig. 1 B). The monophasic time course in the activating
concentration range reﬂects the formation of the A site-
mediated Ca-CaM-like state with low lmax, whereas in the
inhibitory concentration range the initial rapid ﬂuorescence
increase was followed by a spontaneous decay. The decay
phase reﬂects the conformational transition from the A site-
mediated state to the I site-mediated state because in the
stopped-ﬂow experiment, the change in the emission inten-
sity was monitored using an interference ﬁlter with the
window opening at 455 nm and the shift from shorter lmax to
longer lmax accompanied by a decrease in the output signal.
The above model provides reasonable explanations for
some unsolved questions in the recent literature. For in-
stance, according to a recent report of Rodney et al. (31),
CaMBP (0.2–0.7 mM) promoted the occurrence of Ca21
sparks in a highly cooperative concentration-dependent man-
ner. This apparent cooperativity can be explained by our
ﬁnding that the CaMBP activation is immediately followed
by inhibition with a rather small increase in the CaMBP
concentration (cf. Fig. 2). According to our model (Scheme
1), this apparent cooperativity is caused by the second
binding of CaMBP to the inhibition site prompted by the ﬁrst
binding to the activation site located in the CaMLD. The
apparent cooperativity may have also been produced by the
fact that the activation of Ca21 release increases the local
cytoplasmic Ca21, prompting the formation of the A site-
mediated Ca-CaM-like state, and spontaneous Ca21 reuptake
prompts the formation of the I site-mediated apo-CaM-like
state. Rodney et al. (31) have shown that a single amino acid
substitution L3624D resulted in a total loss of activating
function of CaMBP without affecting its ability to bind with
apo-CaM. This is consistent with our proposal that the
interaction of CaMBP with the A site occurs via the N-
terminal F1 region of CaMBP (Scheme 1), also consistent
with previous reports of Hamilton and colleagues (32) and
ours (24) that Ca-CaM binds to the F1 region, whereas apo-
CaM binds to the C-terminal (or F1/F4) region of CaMBP.
This study of CaMBP-badan binding to the expressed
peptide R3534–4271 corresponding to the Met3534–Ala4271
region containing both CaMBD and CaMLD provided us
with some new insight into the location of the CaMBP bind-
ing domain. The binding of CaMBP-badan at a low peptide
concentration produced the Ca-CaM-like low lmax state, and
the binding at a higher peptide concentration produced a
small but appreciable red-shift in the lmax. Interestingly, this
peptide concentration-dependent shift in the lmax is identical
to that seen in the interaction of CaMBP with the RyR1
moiety of SR. This suggests that both of the A and I sites of
the CaMBP binding domain postulated here are located
within the Met3534–Ala4271 region, most probably in the 4064–
4210 CaMLD (cf. 23). However, there is an important dif-
ference between the R3534–4271 and CaM that upon binding
of CaMBP-badan the R3534–4271 produces a Ca-CaM-like
conformational state even at 0.1 mM Ca21.
SCHEME 1 This model assumes that there are two
types of CaMBP binding sites in the CaMBP binding
domain: an A site and an I site. Binding of CaMBP to
the A site via the F1, the Ca-CaM binding region of
CaMBP (red region), produces a conformational
state resembling the CaMBP-badan that is bound
with Ca-CaM (emission maximum at a lower wave-
length), activating the channel and inducing Ca21
release. Upon increasing the concentration of CaMBP,
additional CaMBP binding takes place at the I site.
This produces a new conformational state, resem-
bling the state of apo-CaM (emission maximum at a
longer wavelength) that is bound via the F1/F4
region of CaMBP (black region), resulting in the
inhibition of Ca21 channel and Ca21 release.
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In conclusion, we used the interaction of CaMBP and its
badan-labeled derivative with the RyR1 moiety of the SR
membrane as a spectroscopic model for the study of the
CaMBP-induced local conformational changes in the CaMBP
binding domain of the RyR1 and induced Ca21 release from
the SR. Coordinated studies of Ca21 release kinetics and
spectrometric monitoring of the peptide binding and induced
local conformational changes in the peptide binding region
of the RyR1 suggest a new mechanism in which CaMBP
binds to the two kinetically and spectroscopically distin-
guishable sites producing activating and inhibitory conﬁg-
urations of the CaMBP binding domain of RyR1 (Scheme 1).
The studies of CaMBP binding to R3534–4271 peptide
suggested that the CaMBP binding domain is located within
the 3534–4271 region of RyR1, probably in the CaMLD,
because spectroscopic studies of the CaMBP-CaM interac-
tion suggested that the CaMBP binding domain retains CaM-
like properties.
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